Through integrated transcriptomic and metabolomic analyses, we demonstrate that BRAFi by vemurafenib (PLX4032) significantly enhances FAO in thyroid cancer cells. The pharmacological inhibition of FAO via thioridazine (Thio) synergizes with BRAFi to suppress tumor growth in vitro, in vivo and in a patient-derived organoid...Consistently, functional studies confirm RUNX1's oncogenic role, as its knockdown reduces cell proliferation, migration, and invasion. In conclusion, our work reveals a metabolic-epigenetic axis underlying adaptive response to BRAFi and identifies RUNX1 as a novel oncogene in thyroid cancer.

P2, N=24, Completed, The University of Technology Sydney | Recruiting --> Completed

Conversely, compared with those of the model group, the expression of NPY, SOCS3, NLRP3, ASC, cleaved caspase-1, GSDMD-N, and IL-1β was significantly downregulated, and the expression of POMC and LEPR was significantly upregulated in the medium-and high-dose HLWDD groups and the metformin group. These results collectively indicate that HLWDD ameliorates olanzapine-induced feeding dysregulation by mitigating leptin resistance through suppression of NLRP3-driven neuroinflammatory pathways in the arcuate nucleus.

Pharmacological inhibitors of specific USPs, such as pimozide, trifluoperazine, rottlerin, 6-thioguanine, and costunolide, are highlighted for their potential to inhibit proliferation, metastasis, induce apoptosis, and circumvent therapy resistance across breast cancer subtypes (triple-negative and HER-2 positive). The review highlights the complex and often contradictory roles of USPs in breast cancer and points to the immense promise of targeting these enzymes to develop new and efficacious anticancer therapies.

P3, N=222, Recruiting, Affiliated Hospital of Qinghai University | Initiation date: Sep 2025 --> Feb 2026

P=N/A, N=125, Recruiting, University of Liverpool | Trial primary completion date: Dec 2025 --> Jun 2026

In summary, our study demonstrated that long-term exposure to olanzapine increases circulating plasma levels of TNF-α, thus leading to increased expression of FABP4 protein in white adipose tissue and subsequently inhibiting Dhhc7expression, which correspondingly leads to reduced membrane translocation of GLUT4 and consequent insulin resistance. In conclusion, this study elucidated the signalling pathway through which olanzapine inhibits GLUT4 membrane transport via the TNF-α/FABP4/Dhhc7 axis, thus ultimately leading to insulin resistance.

P=N/A, N=2000, Recruiting, Shandong Cancer Hospital and Institute

P3, N=360, Recruiting, Alliance for Clinical Trials in Oncology | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Apr 2026 --> Apr 2027

P2, N=66, Recruiting, Roswell Park Cancer Institute | Not yet recruiting --> Recruiting

P2, N=180, Active, not recruiting, Central Institute of Mental Health, Mannheim | Recruiting --> Active, not recruiting | Trial completion date: Jun 2026 --> Dec 2027 | Trial primary completion date: Jun 2026 --> Dec 2027

P=N/A, N=60, Completed, Affiliated Hospital of Jining Medical University; Affiliated Hospital of Jining Medical University